ArticleTherapeutic advances in medical oncology2021
ALBI score and outcomes in patients with hepatocellular carcinoma:
Article in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional Study.Liver cancer · 2026Article
- Impact of TACE combined with targeted and immune therapy on liver function and prognosis in unresectable hepatocellular carcinoma patients: the significance of baseline albumin-bilirubin grade.Therapeutic advances in medical oncology · 2026Article
- Immunometabolic Targets in CD8Liver cancer · 2025Review
- ALBI-sarcopenia score as a predictor of treatment outcomes in hepatocellular carcinoma.Scientific reports · 2025Article
- Liver function dynamics in advanced hepatocellular carcinoma receiving immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization.Therapeutic advances in medical oncology · 2025Article
- Amount of ascites impacts survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization advocating for volumetric assessment.Scientific reports · 2024Article
- The Performance of a Survival Nomogram and Albumin-Bilirubin Grade as Prognostic Tools in Advanced Hepatocellular Carcinoma Treated with FOLFOX4.Journal of personalized medicine · 2024Article
- ALBI Grade Analyses of TACE Combined with Anti-Angiogenesis Therapies Plus PD-1 Inhibitors versus Anti-Angiogenesis Therapies Plus PD-1 Inhibitors in Advanced HCC.Journal of hepatocellular carcinoma · 2024Article
- Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2023Article
- The ALBI score: From liver function in patients with HCC to a general measure of liver function.JHEP reports : innovation in hepatology · 2022Review
- The Use of Albumin-Bilirubin Grade in Patients With Hepatocellular Carcinoma.Gastroenterology & hepatology · 2022Article
- Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.Journal of hepatocellular carcinoma · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis post hoc analysis evaluated albumin/bilirubin (ALBI) score, an objective measure of liver function, in patients receiving pembrolizumab plus best supportive care (BSC) compared with placebo plus BSC in the KEYNOTE-240 study.
methodsPatients with confirmed hepatocellular carcinoma (HCC) and progression after/intolerance to sorafenib, Child-Pugh class A liver function, and Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned 2:1 to pembrolizumab 200 mg or placebo intravenously every 3 weeks plus BSC for ⩽35 cycles or until confirmed progression/unacceptable toxicity. Outcomes were assessed by ALBI grade.
resultsOf 413 patients, at baseline 116 had an ALBI grade 1 score (pembrolizumab,
conclusionPembrolizumab did not adversely impact liver function compared with placebo in patients with HCC, as measured by changes in ALBI scores. A trend toward improved overall survival was observed with pembrolizumab in both ALBI grade groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.